Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Binding of human serum proteins to Plasmodium falciparum-infected erythrocytes and its association with malaria clinical presentation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Identification of a conserved var gene in different Plasmodium falciparum strains

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Arnaud Chêne
  • Sophie Houard
  • Morten A Nielsen
  • Sophia Hundt
  • Flavia D'Alessio
  • Sodiomon B Sirima
  • Adrian J F Luty
  • Patrick Duffy
  • Odile Leroy
  • Benoit Gamain
  • Nicola K Viebig
View graph of relations

Placental malaria caused by Plasmodium falciparum infection constitutes a major health problem manifesting as severe disease and anaemia in the mother, impaired fetal development, low birth weight or spontaneous abortion. Prevention of placental malaria currently relies on two key strategies that are losing efficacy due to spread of resistance: long-lasting insecticide-treated nets and intermittent preventive treatment during pregnancy. A placental malaria vaccine would be an attractive, cost-effective complement to the existing control tools. Two placental malaria vaccine candidates are currently in Phase Ia/b clinical trials. During two workshops hosted by the European Vaccine Initiative, one in Paris in April 2014 and the other in Brussels in November 2014, the main actors in placental malaria vaccine research discussed the harmonization of clinical development plans and of the immunoassays with a goal to define standards that will allow comparative assessment of different placental malaria vaccine candidates. The recommendations of these workshops should guide researchers and clinicians in the further development of placental malaria vaccines.

Original languageEnglish
JournalMalaria Journal
Volume15
Pages (from-to)476
ISSN1475-2875
DOIs
Publication statusPublished - 17 Sep 2016

    Research areas

  • Journal Article

ID: 49203896